Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.60 Consensus Price Target from Brokerages

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $8.60.

Several research analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Barclays initiated coverage on shares of Gossamer Bio in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $9.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd.

Institutional Trading of Gossamer Bio

A number of hedge funds have recently modified their holdings of the business. MMA Asset Management LLC purchased a new stake in shares of Gossamer Bio in the 4th quarter worth about $31,000. Soltis Investment Advisors LLC purchased a new position in Gossamer Bio during the 4th quarter valued at about $31,000. Ciovacco Capital Management LLC bought a new stake in Gossamer Bio during the third quarter worth about $27,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Gossamer Bio in the fourth quarter worth about $35,000. Finally, NorthCrest Asset Manangement LLC purchased a new stake in Gossamer Bio in the fourth quarter worth about $36,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $2.26 on Friday. The firm has a market cap of $523.10 million, a P/E ratio of -3.28 and a beta of 1.93. Gossamer Bio has a fifty-two week low of $0.76 and a fifty-two week high of $3.87. The business’s 50 day moving average price is $2.94 and its 200-day moving average price is $2.67.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.